Company: SMNR
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001193125-25-306962
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 0
---
As filed with the Securities and Exchange Commission on December 3, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Semnur Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

| Delaware                        |     | 98-1659463         |
| (State or other jurisdiction of 
 incorporation or organization)  |     | -I.R.S. Employer   
 Identification No. |

Semnur Pharmaceuticals, Inc. 960 San Antonio Road Palo Alto, CA 94303 (Address of Principal Executive Offices) (Zip Code) Semnur Pharmaceuticals, Inc. 2024 Stock Option Plan (Full titles of the plans) Jaisim Shah Chief Executive Officer & President 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Name, address and telephone number, including area code, of agent for service) Copies to: Jeffrey T. Hartlin, Esq. Elizabeth A. Razzano, Esq. Paul Hastings LLP 1117 S. California Avenue Palo Alto, California 94304 (650) 320-1800 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2of the Exchange Act.

| Large accelerated filer |     | ☐ |     | Accelerated filer         |     | ☐ |
| Non-accelerated filer   |     | ☒ |     | Smaller reporting company |     | ☒ |
|                         |     |   |     | Emerging growth company   |     | ☒ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

EXPLANATORY NOTE

This Registration Statement on Form S-8 (this “Registration Statement”) is being
filed by Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”), relating to 46,250,